April 29, 2017
Cato Research and Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2017 PDF

May 10, 2016
Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2016 PDF

May 05, 2016
Manufacturing has begun for Cancer Advances' Lead Product PDF

March 28, 2016
NeuroproteXeon Appoints Cato Research for Phase III Trials

NeuroproteXeon Appoints Cato Research for Phase III Trials

Mervyn Maze, MB, ChB, Chief Medical Officer of NeuroproteXeon announced CATO Research of Durham, North Carolina as the Clinical Research Organization (CRO) administering the Company’s Phase III trial. Dr. Maze indicated the selection reflects CATO’s three decades of experience in international trial administration, their broad international scope, and the ease with which NP and CATO management interacted.

Present plans are for a nine country, approximately 30 sites, 1,300 patent trial, comparing hypothermia with hypothermia plus Xenon. The primary outcome will be survival from cardiac arrest. It is anticipated the trial will be complete in less than two years following FDA/ EMA approval of the Company’s IND application.

 

March 8, 2016
Cancer Advances attends PanCAN PDF

November 2, 2015
Join Cato BioVentures at BIO-Europe in Munich, Germany PDF

October 28, 2015
Cancer Advances Announces $48.5 Million Funding Commitment  PDF

June 15, 2015
Join Cato BioVentures at 2015 BIO International Convention PDF

May 15, 2015
Cancer Advances and Cato Research to Participate PurpleStride: Raleigh-Durham 2015 5K RUN & Family-Friendly Walk for Pancreatic Cancer Awareness and Research  PDF

January 15, 2015
Cancer Advances to attend ASCO Gastrointestinal Cancers Symposium PDF